ViGenCell, NK/T cell lymphoma treatment ‘VT-EBV-N’ designated as orphan drug in Europe

ViGenCell, a company specializing in immune cell therapy, announced on the 19th that its NK/T cell lymphoma treatment "VT-EBV-N" has been designated...

NKMax to perform first tests on dementia cell therapy in US

NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...

NKMax's US subsidiary listed on Nasdaq

South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...

S.Korea’s beauty brand Laneige enters UK, Middle East market

Amorepacific Corp.'s cosmetic brand Laneige announced on Tuesday that it is accelerating its global business expansion by entering the UK and Middle...

Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer

South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, h...

US affiliate of Korea's cell therapy company NK Max eyes NYSE listing in 3Q

NKGen Biotech, the US affiliate of South Korea's natural killer (NK) cell therapy developer NK Max, on Friday said it signed a letter of intent (LOI) ...

GC Cell's AB-101 NK therapy achieves FDA fast-track status

South Korea's bio firm GC Cell announced on Wednesday that its US affiliate Artiva Biotherapeutics has received fast-track designation from the US F...

S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer

South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on ...

Why a Biden presidency means more of the same with North Korea

If the Democratic Party candidate Joe Biden wins the US presidential election next month, as the polls suggest he will, many things will change. The g...